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Introduction
INTRODUCTION
          Cerebral venous thrombosis (CVT), is the thrombosis of the
intracranial veins or dural sinuses.1 It is a relatively rare disorder,
affecting about 5 persons per million per year with huge regional
variations.2 It accounts less than 1% of all strokes. It has differential
geographic distribution with a higher incidence in the Asian countries.
In contrast to arterial stroke, thrombosis of the cerebral venous sinuses
and the cerebral cortical veins most often affects children and young
adults.
  Its presentation is highly variable, etiological factors are diverse
and more heterogeneous making cerebral cortical venous thrombosis
(CVT) a distinctively unique entity.
            The Virchow’s triad, which compromises the features of
endothelial damage, stasis and hypercoagulability of blood, plays a very
important role in the pathogenesis of cerebral venous sinus thrombosis.
These haemodynamic factors vary with each patient. They may operate
together incidentally or accidentally to produce the clinical
manifestation of cerebral cortical venous sinus thrombosis.
2  Before the availability of computed tomography (CT) and
magnetic resonance imaging (MRI), CVT was considered to be a
disorder of infectious etiology that usually results in bilateral or
alternating focal neurological deficits, which was associated with
seizures and coma and usually leading to death. In fact, CVT was
usually diagnosed at autopsy or sometimes at angiography, i.e., in
patients with severe clinical manifestations. The widespread availability
of CT- and MRI-scans has totally  changed our knowledge about the
disease and on its wide clinical spectrum.
Nowadays, in western countries CVT is regarded as a disorder of
non-infective origin with varied  clinical presentations with a favourable
outcome and a case-fatality rate of less than 10%. 1 Heparin is the
treatment of choice and the prognosis nowadays is usually good.
CVT has been a disease associated with a considerable morbidity
in the general population, more so in females during their post partum
period and with a history of intake of OCP. But recent studies show an
increasing incidence in males also. This study aims to try to evaluate
risk and etiological factors that possibly play an important role in the
causation of CVT in males in this part of the city.
Aim of the Study
3AIM OF THE STUDY
To study the risk and etiological factors in pathogenesis of
Cerebral Venous Thrombosis and the varied clinical presentation in
males.
Review  of  Literature
4REVIEW OF LITERATURE - I
ANATOMY OF CEREBRAL VENOUS SYSTEM
The venous system of the brain is distinct from the systemic ones.
They lack valves and   may   have  bidirectional  flow.  The  dural
venous   sinuses   and  cerebral veins   do  not  travel  with  their  arterial
counterparts  and  hence  their  drainage  territories  do  not   mirror
arterial  distributions.  Therefore, a venous "stroke” looks and behaves
differently from an arterial occlusion. Connections   exists  between
venous  sinuses  and   the  veins  of   scalp,  face  and  neck. They  not
only  provide  alternate  route,  but  also  serve  as  a  path  by  which
infection  can  spread  to  venous  sinuses  from  these  areas   to cause
cerebral venous   sinus   thrombosis.
Cerebral venous system can be divided into a superficial and a
deep system.   The  superficial  system  includes the  sagittal  sinus   and
the  draining   cortical  veins  that   drain the   superficial   surfaces  of
both   the  cerebral  hemispheres.  The   deep   system    comprises    of
lateral  sinus,   straight  sinus and  sigmoid  sinus   along  with  the
draining   deeper  cortical  veins . Both these systems mostly drain into
internal jugular veins.
5 Cerebral Veins are divisible into external and internal  veins
which drain   the  external surface   and  the internal region of the
cerebral hemispheres respectively.  The external cerebral veins drain the
superficial part of cerebral hemispheres. The superior cerebral veins
drain the supero lateral and the medial surface of the cerebral
hemisphere.  They ascend upwards, pierce the arachnoid mater, traverse
the subdural space and drain into the superior sagittal sinus.  The middle
cerebral veins drain into the cavernous sinuses and the inferior cerebral
veins into lateral sinuses.
The internal cerebral veins drain blood from the deeper part of
cerebral hemispheres into the great cerebral vein of Galen. The basal
veins of Rosenthal drain part of lower frontal lobe and insula and are
joined by inferior striatal veins and terminate either in the internal
cerebral veins or directly into great cerebral vein. The two internal
cerebral veins drain mainly the basal ganglia, thalamus and
hypothalamus to unite to form the great cerebral vein, which joins the
inferior sagittal sinus to form the straight sinus. Connections exist
between external and internal venous system, which allows blood to
take alternative route, if needed.
6SUPERIOR SAGITTAL SINUS
It is situated in the attached margin of falx cerebri. It commences
at crystal galli and end posteriorly into one of the (usually the right)
transverse sinus. They are occupied by arachnoid granulations for CSF
absorption.
INFERIOR SAGITTAL SINUS
It is situated in the free margin of falx cerebri. It passes
posteriorly and drains into the straight sinus.
STRAIGHT SINUS
It is situated at the junction of falx cerebri and tentorium. It runs
posteriorly and drains into the transverse sinus in the side opposite to
which the superior sagittal sinus has drained. It is formed by the union
of great cerebral vein of Galen and inferior sagittal sinus.
TRANSVERSE SINUSES
These begin at internal occipital protuberances to lie in the
attached margin of tentorium and pass anteromedially to continue as
sigmoid sinuses. The right transverse sinus is usually bigger than the left
7one. In about 4% cases the left sinus may be absent or hypoplastic . The
superior sagittal sinus and straight sinuses drain into one of the
transverse sinus, usually the right.
SIGMOID SINUS
 They continue anteriorly over the mastoid part of temporal bone
to continue as internal jugular vein at jugular foramen.
CAVERNOUS SINUSES
They lie one on each side of the sphenoid bone. They receive
blood from ophthalmic veins, several of the anterior inferior cerebral
veins, the sphenoparietal sinus and the pituitary vein. They are traversed
by number of structures, involvement of which causes clinical
manifestation of cavernous sinus thrombosis. The Internal carotid artery
wrapped by sympathetic plexus passes through it while abducent nerve
lies inferolaterally. The oculomotor and trochlear nerves and the first
and second divisions  of the  trigeminal nerve lie in the lateral wall of
the sinus. The two sinuses are connected by  the  valveless circular sinus
8SUPERIOR AND INFERIOR PETROSAL SINUSES
        The superior petrosal sinus (SPS) courses posterolaterally along
the top of the petrous temporal bone, extending from the cavernous
sinus to the sigmoid sinus. The inferior petrosal  sinus (IPS) courses just
above the petrooccipital   fissure  from  the  inferior  aspect of the clival
venous plexus  to  the jugular bulb.
SPHENOPARIETAL SINUS
The  sphenoparietal sinus (SPS) courses around the lesser
sphenoid wing at the rim of the middle cranial fossa. The SPS receives
superficial veins from the anterior temporal  lobe and drains into the
cavernous or inferior petrosal sinus.
CLIVAL VENOUS PLEXUS
The clival venous plexus (CVP) is a network of interconnected
venous channels that extends along the clivus from the dorsum sellae
superiorly to the  foramen magnum. The CVP connects the cavernous
and petrosal sinuses with each other and with the suboccipital veins
around the foramen magnum.
Figure 1: Cerebral venous sinuses - Anatomy
Figure 2: Anatomy of cerebral venous sinuses
Figure 3: Anatomy of Cavernous sinus
Figure 4: Anatomy of Deep Venous System
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9CEREBRAL VEINS
The cerebral veins are subdivided into three groups:
 (1)Superficial ("cortical" or "external") veins
(2) Deep cerebral("internal") veins
 (3) Brainstem/posterior fossa veins.
 (1) SUPERFICIAL CORTICAL VEINS
The superficial cortical veins consist of a superior group, a middle
group, and an inferior group. Between 8-12 unnamed superficial veins
course over   the upper surfaces of the  cerebral hemispheres, generally
following convexity sulci. They cross the subarachnoid space and pierce
the arachnoid and inner dura before draining into the SSS. In many
cases, a dominant superior cortical vein, the vein of Trolard, courses
upward from the sylvian fissure to join the SSS.
MIDDLE CORTICAL VEINS.
       The most prominent vein in this group is the superficial middle
cerebral vein(SMCV). The SMCV begins over the sylvian fissure and
collects numerous small tributaries from the temporal, frontal, and
parietal opercula that overhang the lateral cerebral fissure.
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INFERIOR CORTICAL VEINS.
These veins drain most of the inferior frontal lobes and temporal
poles The deep middle cerebral veins (DMCV) collects tributaries from
the insula, basal ganglia  and anastomoses with the  basal vein of
Rosenthal  (BVR). The BVR courses  postero  superiorly in the ambient
cistern, curving around the midbrain to drain into the great vein of
Galen.
DEEP CEREBRAL VEINS
The deep cerebral veins may also be subdivided into three
groups: (A) medullary veins, (B) subependymal veins, and   (C) deep
paramedian veins.
MEDULLARY VEINS.
Innumerable small, unnamed veins originate between 1-2 cm
below the cortex and  course  straight through  the  white matter
towards  the  ventricles  where  they terminate  in  the  subependymal
veins. These veins   are generally in apparent on imaging studies
throughout  most of their  course  until  they  converge  near  the
ventricles.
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         (B)  SUBEPENDYMAL VEINS.
The subependymal veins course under the ventricular ependyma,
collecting blood from the basal ganglia and deep white matter (via the
medullary veins). The two most important ones are the  septal veins and
the thalamo  striate veins. The septal veins curve round the frontal horns
of the lateral ventricles, then course posteriorly along the septum
pellucidum. The thalamostriate veins receive tributaries from the
caudate nuclei and thalami, curving medially to unite with the septal
veins near the foramen of Monro to form the two internal cerebral veins.
(A) DEEP PARAMEDIAN VEINS.
Two important paramedian veins, the internal cerebral veins
(ICVs) and vein of Galen (V of G) provides drainage for most of the
deepbrain structures.
The ICVs are paired paramedian veins that course posteriorly in
the cavum velum interpositum, the thin invagination of subarachnoid
space that lies between the third ventricle and the fornices. The ICVs
terminate in the rostral  quadrigeminal   cistern by uniting with each
other and the basal vein of Rosenthal  to form the vein of Galen.
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The vein of Galen (great cerebral vein) curves posterosuperiorly
under the splenium of the  corpus callosum, uniting Brainstem/Posterior
Fossa Veins. The veins that drain the midbrain and posterior fossa
structures are likewise divided into three groups: (1) a superior
("galenic") group, (2) an anterior (petrosal) group, and (3) a posterior
group.
(i) SUPERIOR (GALENIC) GROUP.
As the name implies, these veins drain superiorly into the vein of
Galen. Major named veins in this group are the precentral cerebellar
vein, the superior vermian vein, and the anterior pontomesencephalic
vein.  The precentral  cerebellar  vein (PCV)  is a single midline vein
that lies between the lingula and the central lobule of the vermis.
It terminates behind the inferior colliculi by draining into the
V of G. The superior vermian vein runs over the top of the vermis,
joining the PCV and draining into the great vein of Galen . The APMV
covers the cerebral peduncles.
(ii) ANTERIOR (PETROSAL) GROUP.
The petrosal vein (PV) is a large venous trunk that lies in the
Cerebello pontine  angle cistern, collecting numerous tributaries from
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the cerebellum, pons, and medulla. The PV and its tributaries form a
prominent star-shaped  vascular  collection  that  is sometimes termed
the "petrosal star"  on AP digital  substraction  angiography  or  coronal
CT  venogram.
(iii) POSTERIOR (TENTORIAL) GROUP.
The most prominent veins in these groups are the inferior vermian
veins   which are paired paramedian structures that curve under the
vermis and drain the inferior surface of the cerebellum.
ETIOLOGY
Causes and Risk factors for Cerebral  Vein thrombosis:3
COMMON
? Oral contraceptives
? Prothrombotic conditions
? Deficiency of proteins C, S, or antithrombin III
? Resistance to activated protein C/V Leiden
? Prothrombin gene mutations
? Antiphospholipid, anticardiolipin antibodies
? Hyperhomocysteinemia
? Puerperium, pregnancy
? Metabolic (dehydration, thyrotoxicosis, etc.)
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Less Common
? Infection
? Mastoiditis, sinusitis
? Meningitis
? Trauma
? Neoplasm-related
Rare but Important
? Collagen-vascular disorders (e.g., APLA syndrome)
? Hematologic disorders (e.g., polycythemia, Thrombocythemia,
Leukemia)
? Inflammatory bowel disease
? Vasculitis (e.g., Behçet)
? Drugs (Oral contraceptives, Asparaginase)
? Neurosurgical procedures, Lumbar puncture
  Many  conditions   can    cause  or  predispose  to cerebral  venous
sinus thrombosis  . They   include    medical,  surgical  and  obstetrical
causes . Conditions that predispose to cererbral venous sinus thrombosis
include genetic  and  acquired  prothrombotic disorders,  haematological
conditions, inflammatory systemic disorders, cancer related
prothrombotic states,  pregnancy and puerperium,  infections ,  local
causes such as tumours, arteriovenous  malformations, trauma, central
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nervous system infections and infections of the ear, sinus, mouth, face
and neck. 1  Diagnostic and therapeutic procedures such as, lumbar
puncture, jugular venous  catheterisation and drugs such as hormonal
contraceptives, hormone  replacement therapy, steroids  when especially
combined with a lumbar puncture predispose  to cerebral venous sinus
thrombosis.
Genetic hypercoagulable conditions:
In the International Study for Cerebral Venous Thrombosis
(ISCVT)1, 44% of the patientswere found to have more than one cause
or predisposing factor.  Congenital or genetic thrombophilia are a  group
of diseases which cause  a majority of prothrombotic states according to
the same study.1  Antithrombin III deficiency, protein C and protein S
deficiency , factor V Leiden or the prothrombin gene mutations,4,5
elevated factor VIII levels 6 and elevated levels  of von Willebrand factor
are  associated with an increased risk of CVT. 6 The protein C promoter
CG  haplotype  gene polymorphisms in the coagulation and fibrinolytic
systems, bears  no independent association  in the causation of CVT.
However, this polymorphism increases  the risk in the carriers of the
factor II G20210A mutation with an odds ratio rising from 14.7 (95%
CI: 2.83-75.3) with the factor II mutation alone to 19.8 (95% CI: 2.1-
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186.5) in the combination of both the mutations.7 For classic congenital
thrombophilia and hyperhomocysteinaemia, 8  the risk is increased when
the protein C promoter CG haplotype is associated with estrogen
treatment 7  The testing for congenital thrombophilia should  be
systematically performed in patients with CVT, even when there a clear
cause has been found, for the following important  reasons: (i) the
presence of congenital thrombophilia potentiates the risk of CVT and
(ii) it is important to look for the disorder in family members to start
them on preventive measures. 4, 5
A study from France demonstrated that factor VIII elevations
were commonly associated with cerebral venous thrombosis6, 11
The specific thrombophilias involved in cerebral venous
thrombosis may differ with respect to disorders associated with deep
venous thrombosis.12.
Hyperhomocysteinaemia:
It is an independent and strong risk factor for CVT,  which is
present in 27-43% of  patients and  in 8-10% in the community. 8, 13, 14
The post-methionine load increment of homocysteine has been found to
be  strongly associated with CVT 8  but not  confirmed. 13  No
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independent association has been found between the C677T mutation in
the methylene tetrahydrofolate  reductase gene ( MTHFR ) and CVT. 8, 13
Acquired hypercoagulable disorders:
Acquired coagulation disorders that are recognized as a cause or
predisposing condition for cerebral venous thrombosis include
disseminated intravascular coagulation, heparin-induced
thrombocytopenia 15, plasminogen deficiency, epsilon aminocaproic
acid treatment, sickle cell disease, polycythemia vera, paroxysmal
nocturnal hemoglobinuria, thrombocythemia, antiphospholipid antibody
syndrome16, nephrotic syndrome, thyrotoxicosis,17,18,19  and
hypercoagulability associated with malignancy. Anemia due to iron
deficiency and other causes has also been associated with cerebral
venous thrombosis.20,21,22,23,24
Inflammatory disorders:
 Conditions such as lupus erythematosus, Behçet disease,
sarcoidosis, ulcerative colitis, Crohn disease, and Wegener
granulomatosis are associated with cerebral venous
thrombosis.25,26,27,28,29,30 Cerebral venous thrombosis may be the first
manifestation of an inflammatory systemic disease.
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Structural damage to venous sinuses:
Head trauma and intracranial surgeries are among the most
common structural etiologies of cerebral venous thrombosis. Cutaneous
infections or contusions can injure the diploic veins that connect to the
scalp via emissary veins and drain in the superior sagittal sinus.
Miscellaneous causes:
Other causes of cerebral venous sinus thrombosis reported in
various studies are spontaneous intracranial hypotension, 31
thalidomide, 32 Cushing's syndrome, 33  tamoxifen, 34  erythropoietin, 35
high altitude, 36   phytoestrogens 37  and even Shiatsu massage of the
neck. 38
 Arteriovenous malformations, tumors, carcinomatous meningitis,
arachnoid cysts, local or surgical trauma to the jugular vein, high
altitude exposure,39 and electrical injury have also been associated with
cerebral venous thrombosis.40  Intracranial hypotension and low CSF
pressure syndromes have been associated with cerebral venous
thrombosis.41,42,43,44,45  Thrombosis has also recently been noted as a
complication of ventriculoperitoneal shunting.46.
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Idiopathic causes:
In 20% to 35%. of cases the etiology of cerebral venous sinus
thrombosis remain unknown. 47
 Mechanisms Leading to the Clinical Manifestations
Two different mechanisms have been postulated and identified;
however, they are interrelated in many cases. 3
The occlusion of  a  main sinus or the feeding cortical veins  leads
to vascular congestion ,which  results in localized brain oedema and
resultant  venous infarction . A  block  in  the major   sinus  leads  to
intracranial  hypertension whereas  a  block  in  deep  cortical  veins
leads  to    oedema, venous infarcton  and  petechial haemorrhages  that
merge with each other  and form large haematomas. Cytotoxic oedema
caused by  local ischemia, subsequently damages  the  energy dependent
cellular membrane pumps and induce intracellular  swelling. 3
Vasogenic  oedema  developing  due  to disruption of the blood brain
barrier and engorgement of the brain interstitium with blood eventually
leads to neuronal swelling.
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The occlusion of a major sinus results in intracranial hypertension
due to impaired absorption of cerebrospinal fluid by the arachanoid villi.
The ventricles do not dilate and   hydrocephalus  does  not develop as
ventricular communication with the subarachanoid space remains
patent.
Pathology
When thrombus forms in a dural sinus, venous outflow is
restricted. This results in venous congestion, elevated venous pressure,
and hydrostatic displacement of fluid from capillaries into the
extracellular spaces of the brain. The result is blood-brain barrier
breakdown with vasogenic edema. If a frank venous infarct develops,
cytotoxic edema ensues.
CLINICAL MANIFESTATIONS
Cerebral venous thrombosis presents with a wide spectrum of
clinical manifestations and modes of onset that mimics  many other
neurological disorders which leads  to frequent  misdiagnoses or  delay
in diagnosis.
21
HEADACHE
Headache is the most  frequent  symptom in  cerebral venous
sinus thrombosis.  The two  plausible  hypothesis that    have been
proposed   for  the  mechanism of   headaches  include   the   stretching  of
nerve fibres in the walls of the occluded sinus and local inflammation
caused by it as suggested  by the  enhancement of the contrast  in the
walls of  sinus surrounding the clot. 2
Headache is a consistent complaint in patients from whom a
reliable medical history could be obtained . 48 Most patients who present
with other neurological symptoms often complain of headache at
admission or report a history of headache of unusual type that started a
few days or weeks earlier.48
Headache may occur due to intracranial hypertension.  Patients
with  a prolonged  course  or  with  delayed  clinical  presentation  may
have papilloedema. 49
Headache may be the only manifestation in  CVT , though it may
be difficult to differentiate from other causes like intracranial
hypertension, subarachnoid hemorrhage or meningitis.10,50 Isolated
headache may be of the thunderclap type, mimicking a subarachnoid
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hemorrhage. 10 .Isolated  headaches are usually associated with lateral
sinus thrombosis. 2   Since headache is  almost  always the first symptom
of CVT, it is important to have a high index of suspicion to diagnose
this treatable entity.
Isolated focal neurological deficits
In cerebral venous sinus thrombosis  the presentation  may be a
transient focal neurological deficit mimicking a transient ischemic
attack  or may be a long-lasting focal neurological deficits due to stroke
either due tovenous ischemia ,intra-cerebral haemorrhage or edema;
The diagnosis is sometimes easily made  in a patient with acute
onset headache  who has a known predisposing condition, such as
puerperium. Sometimes the diagnosis will be picked up during imaging
taken for  a suspected arterial stroke.
Diffuse encephalopathy with seizures
Patients with parenchymal lesions, may present with  a more
severe clinical scenario which may include various  degrees of  coma,
motor  deficits or aphasia and seizures (focal or generalized seizures,
including status epilepticus). Seizures may be the presenting features in
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patients with parenchymal lesions, with  sagittal sinus and cortical vein
thrombosis. 51
Other clinical presentations
Varied clinical presentations have been described in cerebral
venous sinus thrombosis 1,52,53,54 which includes attacks mimicking
migraine with aura, isolated psychiatric disturbances, pulsatile tinnitus,
isolated or multiple cranial nerve involvement or subarachnoid
hemorrhage .
Clinical manifestations based on site of venous occlusion
Different types of clinical manifestations occur with  involvement
of the different sinuses :
In occlusions of superficial cortical veins ,sensory  or motor
deficits, seizures may be the presenting features.
 In  superior  sagittal sinus thrombosis  motor deficits that are
sometimes alternating or bilateral may be present . Seizures are also
commonly associated.   Features of intracranial hypertension can also be
the presenting manifestation  in SSS thrombosis.
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Thrombosis of the lateral sinus  may present as an isolated
intracranial hypertension. Patients may also have   associated   aphasia
when the left transverse sinus is involved.
Thrombosis of deep cerebral veins leads to a severe clinical
presentation with coma, delirium and bilateral motor deficits, but
symptoms may be of milder intensity when the thrombosis is limited. 55
In cavernous sinus thrombosis, usually presents with  orbital pain,
chemosis,  proptosis  and  oculomotor  palsies.
Imaging in cerebral venous thrombosis
The key to the diagnosis of CVT   is  the  documentation  of the
occluded vessel or of the intravascular thrombus. The gold standard is
the combination of MRI, which visualizes the thrombus , with magnetic
resonance venography (MRV), which shows the nonvisualization of the
vessel. 4, 56
Cortical venous thrombosis with or without sinus involvement
Computed Tomography
CT scan of Brain with contrast and coronal reconstruction shows
the following:74
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Bony  abnormalities, PN sinuses and mastoid Dense triangle sign-
dural sinuses or deep vein can shown as hyperdense, round or triangular
structures on  non-contrast  axial  cuts  indicating  presence of thrombus
within.
Cord sign-Cerebral cortical vein is seen as high density, thin,
linear structure. This is a  rare but  a specific sign.
Empty delta sign; This  seen in  contrast CT in SSS on coronal
view. The contrast enhances the  walls but  middle lumen with thrombus
does not enhance.
Deep venous system occlusion manifests as  infarct, oedema and
haemorrhages in  the thalamus and basal ganglia.
CT VENOGRAM
 Depicts thrombus as filling defect in cortical veins
 Abnormal collateral channels (e.g., enlarged medullary veins) are
seen
 Limited role in chronic CVT (organizing thrombosis also
enhances).
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MRI
 TlWI:  In T1 sequence, the  clot  is  hyperintense  in the  acute phase.
Venous infarct in T1 is characterised  by  gyral  swelling, associated
with  hypointense  edema, and  may be associated with hemorrhage
 T2WI  :  The  clot  is  often  hypointense  mimicking  flow  void  which
later becomes  hyperintense Venous infarct in T2 shows  gyral  swelling,
hyperintense   edema, and  may   be  .hemorrhagic.
 FLAIR :  In FLAIR  sequence the  thrombus  usually  hyperintense,
oedema looks hyperintense.
T2 GRE : Clot will be hypointense with blooming
 DWI :  DWI/ ADC  imaging  findings  heterogeneous  depending on
the presence of ischemia, type of edema,  hemorrhage
T1 CONTRAST
In the acute/early subacute state the clot enhances in the periphery
 MRV
2D time of flight (TOF) MRV depicts thrombus as sinus
discontinuity, loss of vascular flow signal .
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CONTRAST ENHANCED MRV (CE-MRV)
• Depicts non enhancing thrombus &small veins than TOF
 MR PERFUSION
 T2 Gadolinium perfusion may show extensive venous
congestion, but without perfusion deficits . It may play a role in
detecting venous congestion vs venous infarction in CVT
Ultrasonographic Findings
• Transcranial Doppler (TCD) ultrasound
        Monitor venous flow velocities at ICU bedside
Angiographic Findings
 Conventional: More accurate than MRI, particularly for isolated
cortical vein thrombosis
Imaging Recommendations
 NECT, CECT scans +/- CTV
Conventional DSA most sensitive for CVT (useful if intervention
is planned).
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 Interventional
Treatment with thrombolytics and/or mechanical de clotting.
In the acute stage of thrombosis, MRI  may show flow artefacts
that can lead to false positives and the lack of hyperintense signal on
T1- and T2-weighted images. 2
During the first 2 to 5 days, the thrombosed sinus appears as an
isointense signal on T1-weighted sequences and a hypointense signal on
T2-weighted sequences2   The diagnostic yield of MRV alone,  is limited
because it does not make a clear differentiation between an occluded
sinus and hypoplasia, particularly for lateral sinuses. 4, 56 Even with the
combination of MRI and MRV, the diagnosis can still be difficult, in the
setting of isolated cortical vein thrombosis . If the characteristic cord
sign is not present on  non-contrast enhanced CT  or MRI-scan, 57, 58 a
conventional angiography may sometimes be required. 59 The inter
observer agreement for the diagnosis of the location of CVT is not
perfect, particularly in the case of cortical vein thrombosis. 60
Several studies have shown the value of T2-weighted sequences:
in contrast to T1 , in  T2,  the thrombus  exhibits a  hypointense  signal
with the magnetic susceptibility effect, the signal being similar to that of
T-2 FLAIR – SEQ : SHOWING HAEMORRHAGE
T-2 AXIAL SHOWING MASTOIDITIS  WITH
TRANSVERSE SINUS THROMBOSIS
MR VENOGRAM SHOWING RT. TRANSVERSE SINUS THOMBOSIS
T2 – FLAIR SHOWING SAH WITH SUPERIOR SAGITAL SINUS
THROMOBSIS
T2 AXIAL SHOWING HAEMORRHAGE INFARCT IN
THE RIGHT PARIETAL LOBE
T2 – FLAIR SHOWING EDEMA IN RIGHT TEMPORAL LOBE
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an intracerebral hemorrhage. 61,62,63 A hypointense signal on T2-images
is present in 90% of sites of  CVT on the first MRI-scan, while a
hyperintense signal is detected on T1-images. 63 This excellent
sensitivity of T2 sequences is of major interest within the first 3 days
when thesensitivity of T2 sequences is higher than 90% and that of    T1
-sequences in only 70%. 2,63 Accordingly, a thrombus located in cortical
veins, even in the absence of visible occlusion on MRV, is more easily
detected with T2 (97%) than with T1 (78%) or fluid-attenuated
inversion recovery (FLAIR) <40%). 63 The presence of a hyperintense
signal of the thrombosed sinus on diffusion-weighted imaging may  be
useful to predict nonrecanalization. 66
Although none of the MRI sequences (T1, T2, FLAIR ) has a
sensitivity and specificity of 100%, the diagnostic yield of their
combination together with MRV is so high that conventional
angiography is nowadays almost not required in patients who can
undergo MRI. 2
Neuroimaging of parenchymal abnormalities with MRI and DWI
In contrast to arterial strokes, brain imaging is less significant in
the diagnosis of CVT. 2 It usually shows only nonspecific lesions, such
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as intracerebral hemorrhages or infarcts, oedema  associated with
infarcts or hemorrhages. It can also be normal in up to 30% of patients. 2
The most common pattern is a heterointense signal with normal or
increased apparent diffusion coefficient (ADC), corresponding to
vasogenic edema. 64,65,70,71,73 Only one study showed a decreased ADC in
most patients, suggesting a cytotoxic edema. 72  Rarely there may be a
pattern of decreased diffusion with complete resolution of the lesion on
follow-up in T2-weighted imaging, mostly in patients with seizures. 73
D-dimer measurement
Several studies 75,76,77,78,79  have tested the importance  of D-dimer
measurements, because in patients with deep vein thrombosis of the
legs, a value below 500 ng/mL has a high negative predictive value., In
patients with recent CVT, there is an increase in D-dimer
concentrations; this implies that a low value of D-dimer makes the
diagnosis of CVT unlikely. 76,77,78 However, the negative predictive
value of low D-dimer concentrations is good in patients with encephalic
signs, who anyway should undergo MRI, but not in those with isolated
headache. 79
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Lab Studies.
After making a  diagnosis of CVT, lab investigations are
necessary to look for the various contributory causes for the
prothrombotic  state. Investigations include  complete blood count to
exlude   anaemia ,polycythemia and   megalo blastic states .Abnormally
high ESR might favour a collagen vascular disorder. ANA and Anti-Ds
DNA are  to  be done in suspected collagen vascular disorder.
Antiphospholipid and anticardiolipin antibodies are done when primary
or secondary APLA syndrome is suspected. Elevated SGPT and serum
protein is helpful in screening  for liver disease. Decreased albumin:
globulin ratio, with hyper gammaglobulinemia  favours a hyper
viscosity state. Sickle cell preparation or hemoglobin electrophoresis
may be required in relevant cases. Urine protein is done to screen for
nephrotic syndrome.  D-dimer values may be beneficial in screening
patients for venous thrombosis.  Evaluation for protein S, C,
antithrombin III, lupus anticoagulant, and factor V Leiden mutation
should not be made while the patient is on anticoagulant therapy,
Lumbar puncture is to be done if  a meningitic  process is suspected to
be the cause for the  CVT. EEG may be helpful in evaluating a seizure
focus, may be normal, may show mild generalized slowing, or show
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focal abnormalities if a unilateral infarct occurs, but it does not
genuinely influence diagnosis and management.
The Diagnostic steps should include the following.
(1) To recognize CVT a high index of suspicion and  good clinical
skill is needed,
(2)  Rule out other possible diagnosis  by supporting investigations
like CT and MRI, or sometimes only MR/MR venogram helps to
rule out CVT.
(3)  Clinical evaluation to assess risk factors of thrombophilia by
history and physical examination and  lab tests even when they  is
not confirmed thrombus in any of the venous sinuses.
(4)  Identify all the possible acquired causes investigate when
necessary, if CVT is  the cause or strong possibility.
(5)  Look for possible hereditary causes—if identified or strongly
suspected consider prolonged anticoagulation and avoidance of all
acquired risk factors for thrombosis.
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TREATMENT
Current treatment option for CVT include antithrombotic therapy
with un-fractionated heparin, Low Molecular Weight Heparins, Oral
anticoagulants, intravenous thrombolytic therapy, local thrombolysis by
selective sinus catheterization and combination of thrombolysis and
anticoagulation.
Anticoagulation with Heparin is indicated for most cases of
venous sinus thrombosis patients with or without haemorrhage into
venous infarct, appears to of benefit. Duration of chronic
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anticoagulation with warfarin is not standardised and decision should be
based on the reversibility of the underlying cause, and anatomic issues
of recanalisation and collateral flow. Transvenous cannulation of the
affected sinus with catheter directed thrombolysis and mechanical
removal of thrombus may be indicated in patients have severe deficits
from involvement of deep venous system or extensive involvement of
superficial sinuses.
Review of Literature II
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REVIEW OF LITERATURE – II
1. In a retrospective analysis of 71cases of CVT by Vembu P, John
JK et al.80 treated at Ibn Sina Hospital, Kuwait,  showed  male to
female ratio of 1:1.5and the incidence of Headache was (93%),
seizures was (31%), and focal neurological signs was (37%).
Papilledema with raised intracranial pressure was seen in 20
patients (28%), ovarian hyper-stimulation syndrome with CVT in
one t, Neuro-Behcet`s in 10% (n=7). The venous sinuses involved
were superior sagittal sinus in 59% (n=42), and transverse and
straight sinuses in 54% (n=38). Hemorrhagic venous infarctions
were seen in 18% (n=13).
2. Another study by Abdulkader Daif et al.81 where  40  cases  of
CVT was analysed, In this study,  headache was present in 82%,
papilledema in 80%, focal motor deficits in 27%,cranial nerve
palsies in 12%, coma in 10%, seizures in 10%,  amd meningeal
signs in 2%. The etiology included coagulopathies in 27%,bechets
in 10%, SLE in7%, tumours in 7%,infections in 7% and unknown
cause in 25%.
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3. In a retrospective analysis of 49 patients with confirmed CVT82,
38 were female. Patient’s age varied between 16 and 75 years,
with an average of 42.6 years. Thrombotic risk factors were found
in 43 patients; the most frequent was dyslipidemia (n = 22)
followed by oral contraceptive use (18). Right
transverse sinus was the most common location
of thrombosis (36).  Only in four cases thrombosis did not involve
the lateral sinuses.
4. Algahtani HA et al.83 retrospectively analysed 111 CVT patients
from  January 1990 – November. 92 were adults and 19 were
children. Among adults, females predominated, while more boys
were affected than girls. The mean age of presentation was 29.5
years. The most common clinical presentations were headache,
focal neurologic deficits, seizures, papilledema, and decreased
level of consciousness. The main risk factors identified were
pregnancy/ puerperium, antiphospholipid antibody syndrome, oral
contraceptive pills, malignancy, and infections. Multiple sinuses
were affected in 51 patients (45.9%). When a single one was
involved, the superior sagittal (24.3%) was the most common.
Seventy-four patients recovered completely, 23 patients recovered
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partially, and 10 patients died. Bad prognostic factors included
incurable co-morbid conditions, late presentation, and status
epilepticus.
5. In a prospective study in Sudan, during the period from February
2001-October 2006 by Mohamed-Nagib A Idris et al.84 included
15 patients, where 12 were females and 3were males with a mean
age of presentation 0f 33.9. Headache (n=15), papilledema(n=13),
paresis (n=3), and generalized seizures(n=3) were the most
common symptoms, and signs encountered. A prothrombotic risk
factor was identified in 12 patients.
6. Another study from India by Brig S Kumaravelu, Maj A Gupta,
Brig KK Singh et al.85 where Sixty consecutive patients of CVT
were managed over a five-year period (2000-2005) in two referral
hospitals of the Armed Forces. The age of patients ranged from 5
to 60 years with a mean of 34.97 ± 8.64 years. Majority (75%) of
our patients were in 3rd and 4th decades of life. Male female ratio
was 11:9. Presenting symptoms were headache in 45 patients,
focal neurologic deficits in 38, seizures in 22, fever in 4, jaundice
and injury in 2 each. Examination revealed focal neurologic
deficits in 51, papilleoedema in 40, meningeal signs in 12 and
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concomitant deep vein thrombosis in 10. Eight patients did not
have any neurologic deficit. Evaluation of etiological factors
revealed puerperium in 16, anemia in 11, meningitis, oral
contraceptive use and systemic lupus erythematosus in three each,
antiphospholipid syndrome, protein C deficiency and protein S
deficiency in two each with one patient showing factor V Leiden
mutation. Two patients came from high altitude without any other
risk factors. CT scan was normal in 19 patients. Venous
hemorrhagic infarcts was seen in 20, nonhemorrhagic infarcts in
eight, empty delta sign in eight and diffuse cerebral edema in six
cases. Magnetic resonance imaging showed thrombosis of
superior sagittal sinus in 44, transverse sinus in 20, straight sinus
in 13, sigmoid sinus in nine and cavernous sinus in two patients.
Isolated venous infarcts were seen in four patients. Twenty-three
patients had hemorrhagic infarcts while nine had nonhemorrhagic
infarcts. One patient underwent a four vessel digital substraction
angiography that showed superior sagittal sinus thrombosis.
7. In a study by Wasay et al86 from United states,  prospectively and
retrospectively 1991-2001 which included 10 centres ., Headache
was seen in 129 (71%)  Focal motor or sensory deficits in  66
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(36%), Nausea/vomiting in 63 (35%),Seizures in 59 (32%),
Drowsiness in  51 (28%),Visual blurring in 42 (23%),  Slurred
speech/inability to speak in (16%), Coma in  27 (15%) and Fever
25 (14%). Neurologic examination findings include Normal
neurologic examination result 69 (38%) ,Confusion/drowsiness
55 (30%), Coma in 37 (20%), Dysarthria 37 (20%), Aphasia 9
(5%),  Papilledema in  59 (32%), Diplopia in  12 (6%) , Cranial
nerve palsies in  33 (18%) Monoparesis  in 3 (2%) , Hemiparesis
71 (39%), Paraparesis in 1 ,Ataxia in  25 (14%). According to
anatomical localisation of the sinus involved, SSST alone 12
(6%),  SSST and TST 9 (5%) SSS and TST 1 St S 2 (1%) and
COVT/DCVT 3, SSST with TST with COVT/DCVT 1. Lab
investigations showed  Systemic lupus erythematosus/
antiphospholipid antibody in 7 (4%),  Protein-C deficiency 3 (2%)
Protein-S deficiency in   4 (2%), Antithrombin III deficiency  in
1, Homocystinemia in  9 (5%), Pregnancy/puerperium 13 (7%)
and  Malignancy 12 (7%).
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8. In a multinational (21 countries), multicenter (89 centers),
prospective observational study called international study on
cerebral vein and dural venous sinus thrombosis by Jose M.
Ferro et al,87 Patients were followed up at 6 months and yearly
thereafter. Primary outcome was death or dependence as assessed
by modified Rankin Scale (mRS). The study was started in May
1998 and continued until May 2001. Patients were followed up
from diagnosis to December 31, 2002.  624 patients were
included in the study from 89 centres in 21 countries. In this study
headache  was present in  88.8%, visual loss  in 13.2%,
papilledema in 28.3%,  diplopia  in 13.5 % , stupor or coma
13.9%,  aphasia  19.%, aparesis in   37.2 %,  bilateral motor signs
3.5 %, focal seizure in 19.6%,  seizure with generalization  in
30%,   Any  seizure   39.3%,  Sensory  symptoms   5.4  %.  Risk
factors studied showed Thrombophilia in 34.1%,
Antiphospholipid antibody in 5.9%, Nephrotic syndromein 0.6%,
Hyperhomocysteinemia in 4.5%, Malignancy in 7.4%.
Hematological conditions in 12%, Vasculitis in  19.3% , Systemic
lupus erythematosus 7.1%, Behçet disease 6.1% Puerperium in
13.8%, Infections in  12.3%, Ear, sinus, mouth, face, and neck
8.2% , Drugs in 7.5%, Radiological features include Superior
41
sagittal sinus involvement in 62.0%, Lateral sinus- left in 44.7%,
Lateral sinus- right in 41.2% , Straight sinus in 18%, Deep venous
system in 10.9%, Cortical veins in 17.1% , Jugular veins  in
11.9%, Cerebellar veins 0.3%, Cavernous sinus 1.3%.
9. In  a  study  by Breteau et al 88 from france from 1995-1998,
Headache occurred in 30.9%, Focal deficits in 47.3%,  Focal or
generalized seizures in  50.9%, Impaired consciousness in 18.2%,
Decreased visual acuity in  5.5%, Site of sinus occlusion, Superior
sagittal sinus occurred in  37%, Lateral sinus in  38%, Straight
sinus in   6%. Factors found to cause CVT included Unknown
causes  in 21.8% , Local infection 5.5%, Cancer 9.1%,
Puerperium 5.5%, systemic lupus erythematosus  1% , Crohn’s
disease 1%, Any coagulation disorder 18.2%, protein C
deficiency 2% , Protein S deficiency 4%, Factor V gene mutation
1%, Prothrombin gene mutation 3% and Oral contraceptive use in
52.2%
10.In a study conducted by Subash Koul et al89 in Nizams institute
of medical sciences in Hyderabad in India in 2012, males
constituted 53.5% mean age of onset was 31.8. Headache was the
presenting feature in 94%, vomiting in 74%, seizures in 45%,
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hemiparesis in 25%, papilledema in 63%, hyperhomocystinemia
was   found  to  be  a  risk  factor  in18.2%,  alcohol  consumption  in
15%,  protein  C  in  9%,  protein  S  in  5.1%,  ACLA   IN  7.2%,
infection in 9%, malignancy in 0.9%. Among  sinus involvement,
SSS along with other sinus involvement was 54.3%, right TS
involvement in 31%, left TS in 16%, SG in 20.6%, ST in 4%,
deep CVT  IN 5.8%, Cavernous sinus thrombosis in 2.4%.
Materials & Methods
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METHODS AND MATERIALS
STUDY DESIGN:
Patients with CVT confirmed by imaging studies enrolled in the
Dept. Of Neurology from June 2011 to Feb 2013 were included in this
study. During the period of admission, patients were evaluated with
demographic profile, detailed history with special importance to risk
factors like smoking, Alcohol consumption including binge alcohol
intake prior to onset of symptoms, substance abuse and clinical
examination for various neurological presentations. These patients were
evaluated with complete blood count to rule out anaemia/
polycythemia, other blood investigations that are implicated in the
pathogenesis of CVT.
STUDY POPULATION:
The study population include male patients who were admitted
with acute headache and other neurological features with CT/MRI/MRV
(brain) finding of Cerebral Venous Thrombosis in the Department of
Neurology, Government Stanley Hospital, and Chennai.
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Inclusion Criteria
Patients included in this study were
A. All adult male patients with features of CVT confirmed by
CT/MRI brain.
Exclusion Criteria
1. All female patients with CVT.
2. All cases of CVT due to Trauma and neoplastic diseases.
3. Children less than 13 years.
STASTISICAL ANALYSIS
Data was analyzed using SPSS 17.0 Software. Mean for the
values were calculated.  Variables were compared using Chi-square test
a P < 0.05 was considered Statistically Significant.
 Results
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RESULTS
Most of the studies done so far have been for CVT in general
including both males and females or had been for puerperal CVT only.
Due to the increased case input of male CVT, a prospective
observational   study was conducted at Department of neurology, Govt.
Stanley medical college, Chennai.
1. AGE:
According to the present study, the mean age of onset of CVT in
males is 35 years. The range was from 13 years to 63 years. The peak
incidence occurred in the age group of 21-25 and 31-35.
Figure 1 – Age Incidence of CVT
Table 1: Age Incidence of CVT
AGE (yrs)
>2
0
21
-2
5
26
-3
0
31
-3
5
36
-4
0
41
-4
5
46
-5
0
51
-5
5
55
-6
0
>6
0
INCIDENCE 1 14 10 12 7 10 6 1 1 1
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2. RISK FACTORS:
Smoking and alcohol were noted as risk factors, both were present
in 82% of the individuals. History of binge alcohol was present in most
of the patients.
            Table 2: Smoking and Alcohol as risk factors
Parameters
Present
(n)
Percentage
Absent
(n)
Percentage
Smoking 49 82% 11 18%
Alcohol 49 82% 11 18%
Figure 2: Risk factors for CVT – Smoking & Alcohol
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3. CLINICAL MANIFESTATIONS
A. Headache:
Headache was the most common clinical manifestation noted in
our patients. All of our patients (100%) presented with headache.
Figure 3: Headache
B. Vomiting:
Vomiting was present in 65% o the patients.
                         Figure 4: Vomiting
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C. Seizures:
Seizures was present in 80% of the patients, both generalised and
focal seizures were noticed.
                       Figure 5: Seizures
Table 3: Symptoms
Headache 60 100% 0 0% 60
Vomiting 39 65% 21 35% 60
Seizures  48 80% 12 20% 60
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D. DIPLOPIA
Diplopia was present in 37% of patients. This was due to either
lateral rectus weakness due to raised ICT and due to the involvement of
multiple cranial nerves in cavernous sinus thrombosis. Patients with
papilledema also had blurring of vision.
Figure 7: Diplopia
E. PAPILLEDEMA:
Papilledema was present in 40% of patients
                                    Figure 8: Papilledema
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F. FOCAL MOTOR DEFICITS
Foal motor deficits in the form of hemiparesis or monoparesis
was present in 47% of the patients. Most of them recovered following
treatment. 15% had a residual weakness.
Figure 9: Focal motor deficits
G. Aphasia
Aphasia was one of the presenting feature in 13% of the patients
.Motor aphasia was the most common form noticed.
Figure 10: Aphasia
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                            Table 4: Signs
Parameters
Present Absent
TotalNo. of
patients
%
No. of
patients
%
Aphasia 8 13% 52 87% 60
Hemiparesis 28 47% 32 53% 60
Papilledema 24 40% 36 60% 60
Diplopia 22 37% 38 63% 60
LAB PARAMETERS
                          Table 5: Prothrombotic workup
Parameters
Negative Positive Total
n  % n  %
ANA 50 83% 10 17% 60
LA 59 98% 1 2% 60
Anti Cardiolipin Ab 57 95% 3 5% 60
Protein C 60 100% 0 0% 60
Protein S 60 100% 0 0% 60
Antithrombin III 58 97% 1 2% 60
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Figure 11: Prothrombotic workup
ANTINUCLEAR ANTIBODY
Anti nuclear antibody was positive in 10 of our patients which
comprised 17%.
                              Figure 12: ANA in CVT
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LUPUS ANTICOAGULANT (LAC)
LAC was positive in only one of our patient
Figure 13: LUPUS ANTICOAGULANT
ANTICARDIOLIPIN ANTIBODY (ACA)
ACA was positive in three of our patients.
Figure 14: ANTICARDIOLIPIN ANTIBODY
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ANTI THROMBIN III DEFICENCY
Antithrombin III deficiency which is a risk factor for
hypercoagulable state was positive in one of our patient.
Figure 15: Antithrombin III deficiency
SERUM HOMOCYSTEINE   LEVEL
Table 6: Homocysteine level in CVT
Parameters ELEVATED NORMAL
Homocysteine 35 25
Figure 16: Homocysteine level
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Serum homocysteine levels were elevated in 35 of our patients
totally. Of these 35, 32 patients were alcoholics, with a history of binge
alcohol in most of them. Only three patients were non alcoholics.
 With these values hyperhomocystenemia can be considered as an
important cause of the hypercoegulable state which might be
contributory to the pathogenesis of CVT in this subset of patients.
CHI-SQUARE TEST-ALCOHOL AND SERUM
HOMOCYSTEINE LEVELS
Table 7
Alcohol
Consumption
Elevated Normal
Total ?2
P-
Valuen % n %
Absent 3 27% 8 73% 11
5.346 0.021*
Present 32 65% 17 35% 49
Chi –square test computed on values of homocysteine and alcohol
showed a significant p value between the two indicating a stastically
significant association between the two.
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INCIDENCE OF SINUS INVOLVEMENT
Table 8: Incidence of Sinus involvement
Parameters SSS TS SG HE DEEP CAV
N 43 26 16 18 9 2
% 72 42% 23% 30% 15% 3%
Figure 17: Incidence of Sinuses involvement
The most common sinus involved is the superior sagittal sinus
43(72%) patients presented with superior sagittal sinus involvement
either alone or in combination. Out of the 43, I5 SSS involvement alone.
13 had associated transverse sinus involvement also. One patient had
involvement of SSS and Sigmoid sinus involvement. Deep vein
thrombosis along with SSS was noticed in 2 patients. SSS with TS with
SG involvement occurred in 5 patients. In SSSS thrombosis,
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haemorrhage occurred in 9 patients in which 2 had associated SAH
( Subarachanoid haemmorage). Two patients were associated with
SAH alone.
Table 8: Multiple sinus involvement with SSS
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No. of patients 28 13 1 6 2 1  11  4 4
Transverse sinus (TS) involvement either alone or in combination
with other sinus involvement occurred in 26 of the patients. Out of the
26 patients, 13 had thrombosis of TS+SG. 2 patients had TS+SG+
haemmorhage. Only 2 patients had isolated TS with haemorrhage
Table 9: Transverse sinus involvement
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No. of patients 4 9 9 6 13 26
Deep CVT was present in 9 of the patients. 8 out of 9 patients had
associated superior sagittal sinus thrombosis. Only 1 patient with
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transverse sinus involvement had associated deep sinus thrombosis. 2
out of the 9 patients with deep CVT died.
OTHER ASSOCIATIONS IN MRI-BRAIN
                      Table 10: Associated Lesions
Parameters
Present Absent
Total
n % n %
Sinusitis 8 13.3% 52 86.7% 60
Granulomas 1 2% 59 98% 60
Carcinoma related 2 4% 58 96% 60
Other associated features in the imaging included sinusitis,
mastoiditis, granuloma and carcinoma related findings.
SINUSITIS
Sinusitis was present in 8 out of 60 patients.
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MASTOIDITIS
Mastoiditis is present in 6 patients. All 6 patients had transverse
sinus thrombosis either alone or in combination with other sinus
involvement.
Fishers’ exact test showed an extreme significance stastistically
for this association.
Table 12: Association between TS and Mastoiditis
TS/
Mastoditis
Absent Present
Total ?2 P-Value
n  % n  %
Absent 34 100% 0 3% 34
43.619 <0.001*
Present 20 77% 6 20% 26
GRANULOMA
One patient had an associated granuloma with sinus thrombosis.
He had a high parietal infarct with superior sagittal sinus thrombosis
along with haemorrhage
CARCINOMA
Two patients had thrombosis adjacent to carcinomatous condition.
One patient had an embryonal  rhabdomyosarcoma abuting the left
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sigmoid and transverse sinus. The other patient had thrombosis of the
right internal jugular vein due to destruction of wall of jugular foramen
due to metastasis.
PROGNOSIS
Out of 60 patients in the study, 2 patients died , 8 patients  had
persistent neurological deficit. The rest improved (50= 83%)
Discussion
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DISCUSSION
The present study   has been conducted at Stanley medical college
in Chennai. Stanley medical college caters a major part of north
Chennai, whose inhabitants are mostly manual labourers. Alcoholism is
very rampant in this part of the city, which is the area where harbour is
located. Hence handling of goods and cargo is the major occupation of
the men in this area which is the reason given by the inhabitants as a
reason for increased alcohol consumption. Women alcoholics are also
common here and women getting admitted in the medical
gastroenterology ward for alcoholic liver disease are not uncommon.
  An earlier study of cerebral venous sinus thrombosis done in the
department of medicine  in 2010 in Stanley Medical College  showed a
higher incidence of CVT in males in contrast to studies available at that
time. Hence this study was exclusively done in male patients to try to
find a possible etiological background for the increased incidence of
CVT in males in this part of the country with the possible available
resources in a government hospital set up.
  Males to female ratio in various studies like Mohammed najib et
al.84, santo gr et al., Vembu et al.80 is favouring a female preponderance.
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But in studies by kumaravelu et al.85 and by Subash Kaul et al.89
(both studies from India) there is a male preponderance.
AGE
Age of incidence varied from 13 years to 63 years in the study.
The study did not include paediatric patients. Hence children below 13
years were not included in the study. Average age of onset was 35 years
with a peak incidence in the third and fourth decade. The results were
consistent with the other studies by Subash kaul et al. 89, Algatani et
al.83, Mohammed najib et al.84 and Brig. S.Kumaravelu et al.85 which
also have similar age incidence. But all the available data are only for
CVT in common and not for male CVT alone.
RISK FACTORS
Smoking and alcoholism   can be considered as a risk factor
according to this study. 82% of patients were smokers and/or alcoholics.
H/O substance abuse was present in many patients but since the
substance abused were native substances whose composition was not
known, so it was not included in the study. But the possible contribution
to the hypercoagulable state by these substances cannot be ignored. The
chemical components of these substances are not constant. Hence it is
63
assumed that their contribution to the hypercoagulable state by these
substances could be significant and it needs a separate study.
CLINICAL FEATURES
SYMPTOMS
Headache is the cardinal symptom noted in the study. All patients
had a history of recent-new onset headache. 100% of patients had
headache at presentation. Head ache as a presenting feature was present
in 93% in a study by Vembu et al.80, in 82% in Abdulkader Daif et al.81,
100% in a study by Mohammed Najib et al.84, 75% in a study by Brig.
S. Kumaravelu et al.85, 71% in a study by Wasay et al.86, 88% in ISCVT,
87 30.9 in Breteau et al.88, NIMS study 94%.89
Vomiting was present in 65%, of our patients. In the study by
Wasay et al.86, vomiting was found in 35% of patients and in the NIMS
study89 vomiting was present in 74% of the patients.
Diplopia / blurring of vision was present in 37% of our patients.
Though blurring of vision was the predominant complaint, diplopia was
also seen in patients with features of increased intracranial tension and
in patients with cavernous sinus thrombosis who had cranial nerve
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palsies. Blurring of vision was present in a study by Wasay et al.86
23.1%, ISCVT87 in 13.5%, Breteau et al, 88 5.5%
Seizure is a manifestation in 80% of our patient’s. They were both
focal and generalised. Seizure was present in 31% in a study by Vembu
et al.80, 10% in the study by Abdul Kader et al.81,  36% in the study by
Brig. S. Kumaravelu et al, 86 39.3% in ISCVT87, 50.9 % in the study by
Breteau et al.88, and 45% in the NIMS study89.
A wide degree of variation has been noted in the incidence of
seizures among the various studies- our study showing the highest
incidence. The high incidence of seizures in our study can be attributed
to multiple causes. The high prevalence of alcoholism in our patients
could itself be a cause of seizures – seizures could either be a rum fits
secondary to binge alcohol intake, or due to a withdrawal state
following the symptoms of headache and generalised ill health noted by
the patient, which might have led to him acutely withdraw the alcohol
which might have caused a withdrawal seizures. The presence of
multiple sinus thrombosis and an extensive involvement of these, with a
resultant haemorrhage may be causative factors for seizures in these
patients.
65
SIGNS
PAPILLEDEMA
The incidence of papilledema in our study was 40%. In   other
studies varies from 28% to 86%. In ISCVT87 the incidence is 28.3% ,
28% in a study by Vembu et al.80 , 80% in the study by Abdulkader et
al.81, 86% in the study by Mohammed Najib et al.84, 66% in the study by
Kumaravelu et al.85, 32% in Wasay et al.86,  and in the NIMS study89 it
was 63%.
APHASIA
13% of our patients develop aphasias. The speech difficulties
varied from slurring of speech to pure aphasias. Deepening on the site
and side of the infarct or haemorrhage, the presentation varied. In the
ISCVT87, aphasia was present in 19% of the patients. In the study by
Wasay et al.86 the incidence of speech abnormality was 16%. The
incidence of speech abnormalities coincides with our data too.
FOCAL NEUROLOGICAL DEFICIT
47% of our patients had focal neurological deficits in the form of
monoparesis, hemiparesis or cranial nerve palsies. The range of foal
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deficits varied in different studies from 25% to 66%. It was 25% in the
NIMS study89, 27% in Abdul kaders et al.81 study, 37% in the study by
Vembu et al.80, 63% in Brig. S.Kumaravelu et al.85, 66% in the study
 by  Wasay  et  al.86, 37.2% in ISCVT87 and 47.3% in the study by
 Breteau et al.88
LAB PARAMETERS
Prothrombotic states considered in the study included serum
ANA, Lupus anticoagulant, Anticardiolipin antibody, Antithrombin III,
Protein C, Protein S, and  Serum homocysteine levels. ANA was
positive in 17% of our patients.  In other studies, ANA  was positive in
7% of patients in the study by Abdul Kader et al.81,5% in S.Kumaravelu
et al.85,4% in Wasay et al.86, and 7% In ISCVT.87
Anti Thrombin III was positive in 2% of our patients. In the study
by Wasay et al.86, it was positive in 1% of his patients.
Protein C and Protein S deficiency was not present in our study.
Lupus anticoagulant was present in 2% of our patients. Anticardiolipin
antibody was present in 5% of our patients.
Serum Homocysteine levels were elevated in 55% of our patients.
In other studies it was not so much elevated. Elevated homocysteine was
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studied in three other studies. In the study by Wasay et al.86 the it was
elevated in 5% of the patients. In the ISCVT87 hyperhomocystenemia
was present in 7% of the patients. In the study from NIMS89,
hyperhomocystenemia was present in 18% of the patients. Chi –square
test computed on values of homocysteine and alcohol showed a
significant p value between the two indicating a statically significant
association between the two in our study.
HOMOCYSTEINE  ELEVATION IN ALCOHOLICS
Homocysteine is a thiol containing aminoacid which is derived
from the aminoacid methionine. It is produced entirely from the
methylation cycle as it is absent in the dietary sources. Homocysteine is
remethylated to methionine. This conversion is catalysed by methionine
synthese or by transsulphuration to cysteine. The latter reaction is
catalysed by cystathionine ? synthese.vitamin B-12, B-6  are eassential
co-factors and folic acid is an essential co-substrate for the
remethylation of homocysteine. It is plausible that the tissue folate
concentrations are closely associated with regulation of homocysteine
metabolism and homocysteine concentration bear an inverse correlation
with the above vitamins90.
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Figure 21: METABOLISM OF HOMOCYSTEINE
In a study by Bleich et al90,it was found , in patients with alcohol
intake , the levels of homocyteine was elevated and levels of folic acid
was decreased. They also documented a gradual decrease in
homocysteine levels in the following week with withdrawal of alcohol.
They also postulated that the alcohol withdrawal symptamatology is due
to the to the increased levels of aspartate and glutamate along with their
sulpanated derivative –homocyteic acid and cysteine sulphinic acid
along with upregulation of NMDA receptors result in excito toxicity
which result  in the withdrawal symptoms.
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In  a  study  by  Robert  M  Russel  et  al.9l, the increased urinary
excretion during ethanol ingestion was documented using radio labelled
studies. In another study by Charles H Halsted et al.92, it was
documented by radiolabelled studies  that there is a decreased jejunal
intake of radiolabelled folate in alcoholic patients.
In a study entitiled hyperhomocysteinemia in cerebral venous
thrombosis by Ida Martinelli et al.93  it was found that patients with
hyperhomocysteinemia had a 4 fold risk of cerebral venous sinus
thrombosis.
With the above references, hyperhomocystenemia which has been
present in 55% of our patients could be secondary to the high incidence
of alcoholism and binge alcohol intake in the study group. The alcohol
related derangements in folate metabolism could be the reason for
hyperhomocystenemia in our patients  manifesting as cerebral venous
sinus thrombosis.
ASSOCIATED LESIONS CAUSING CVT
Mastoiditis was documented in MRI Brain in 10%. Granuloma
was associated as cause of the adjacent cortical veins thrombosis
resulting in the thrombosis of the adjacent SSS resulting in
haemorrhagic infarct in one patient.
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Sinusitis was associated with cavernous sinus thrombosis in one
patient. Another patient with cavernous sinus thrombosis which was a
recurrent episode did not have sinusitis in imaging, but had
hyperhomocystenemia.
2 (3.3%) of the patients had thrombosis  in sinuses adjacent to a
malignant infiltration.  One patient had a lesion suggestive of an
embryonal cell carcinoma in the left mastoid bone with thrombosis of
the left sigmoid sinus. The other patient had a lesion suggestive of a
metastasis in the right jugular foramen and thrombosis of the contiguous
right jugular foramen and sigmoid sinus.  Quoting other studies, the
incidence of malignancy was 7% in abdulkader et al.81, 7% in study by
Wasay et al.86, 7.4% in ISCVT87, 9.1% in Breleau et al.88 and 0.9% in
the NIMS study87. The varied incidence may be due to availability of
specialised oncological units which is not present in our institution.
ANATOMICAL LOCALISATION IN IMAGING
All of our patients were subjected to MRI brain with MR
Venogram, MR angiogram, diffusion weighted sequences and ADC
mapping and gradient echo sequences.
The anatomical localisation of the sinus involvement is as
follows:
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The superior sagittal sinus (SSS) was involved along with other
sinus in 43 (72%) patients.  SSS was involved alone in 28 patients
(46%). SSS was involved along with transverse sinus (TS) in 13 patients
(21.6%).  SSS  was  associated  with  TS  and  sigmoid  sinus  (SG)  in  6
patients (10%). SSS is present with deep vein thrombosis in 8(13.33%)
SSS was associated with haemorrhage/haemorragic infarct in 11
patients(18.3%). 4 patients had subarachanoid haemorrhage associated
with SSS thrombosis- out of which two were associated with
haemorrhage and two had isolated SAH. SSS involvement along with
TS with sigmoid sinus (SG) and haemorrhage is present in 2(3.3%). SSS
is associated with transverse sinus with haemorrhage in 1 pt (1.6%).
Transverse sinus (TS) involvement is present in 26 patients
(43.3%)   together along with other sinus involvement. Isolated TS
thrombosis is present in 4 patients (6.6%).  TS is associated with SG in
9 (15%) patients. TS is associated with deep venous sinus thrombosis in
3(5%) patients.TS is associated with haemorrhage in 6 patients (10%).
Mastoiditis is present in 6 patients (10%). All patients with
mastoiditis have associated tranverse sinus thrombosis. The fishers exact
table was used to find out association between mastoiditis and
transverse sinus involvement. The test has a stastistically significant
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association between the two with a p-value of < 0.0001 postulating a
strong association between the two.
Sigmoid sinus involvement is present alone in only one patient.
With other combinations it is present in 19 patients (31.6%).  SG and TS
sinus involvement is present in 11 patients (18.3%)
TS +SSS+SG is present in 5 patients. SG thrombosis is present
with IJV thrombosis in one patient with metastatic lesion in the jugular
foramen. SG +SSS+ Deep system +haemorrhage is seen in one patient,
SG+SSS+Deep vein thrombosis is noted in one patient.
Cavernous sinus thrombosis is present in 2 of our patients (3.3%)
one patient was associated with sinusitis and in other patient sinusitis
could not be documented. But in the second patient
hyperhomocystenemia was a risk factor.
Deep vein thrombosis is present in 9 (15%) of patients. 8 (13.3%)
had associated SSS thrombosis also. 4 patients had a combination of
SSS+TS+ DEEP vein sinus thrombosis. 2 patients with extensive CVT
with deep vein thrombosis who presented with GCS less than 8, died.
Haemorrhage is present in a total of 18 (30%) of patients. SSS is
associated with haemorrhage in 11 patients. Haemorrhage is associated
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with TS in 6 (10%) of patients. Deep CVT is associated with
haemorrhage in 5 patients (8.33%). Subarachanoid haemorrhage (SAH)
was associated in 4 patients .of the 4, 2 had associated haemorrhage, but
the remaining two were associates with SAH in the presence of SSS
thrombosis. SAH is not a common manifestation in CVT. It is
postulated to the rupture of cortical veins abutting the surface which
results in SAH.
Table 13: Site of CVT in various studies
Sinus
involved
Vembu
et al.80
Brig.
S.kumaravelu
et al.85
Wasay
et al.86
ISCVT87
NIMS
STUDY89
Present
study
SSS 59% 73% 62% 37% 37.3% 72%
TS 54% 33.3% - 18% 47% 43%
SG 3.3% 20% 31%
CAV 1.3% 2.4% 3%
Deep CVT 11% 5.8% 15%
Haemorrhage 18% 15% 30%
PROGNOSIS
Out of 60 patients in the study, 2 patients died, 8 patients had
persistent neurological deficit. The rest improved (50= 83%).
Conclusion
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CONCLUSION
Cerebral venous thrombosis (CVT) which was previously thought
to be an uncommon condition is now being diagnosed frequently due to
increasing awareness and improvement in imaging modalities. Cerebral
venous sinus thrombosis presents with a wide variety of clinical
manifestation, the most common being acute onset headache, seizures,
features of raised intracranial tension and focal neurological deficits not
pertaining to arterial territorial region.
Thrombophilic conditions and hyper oestrogenic states in a
setting of dehydration are known factors postulated in the causation of
CVT. This study, exclusively done in male patients is the first of its kind
to our knowledge from the literature. From the results obtained in this
study, alcoholism, which is very much rampant in this part of Chennai,
seems to be cause for the higher incidence of CVT in males. The
correlations of the various studies quoted from the literature, makes it
plausible to consider folate deficiency in alcoholics with the resultant
hyper homocystinemia as the cause for the hyper coagulability. Further,
in our study group which includes people who are manual labourers,
belonging to low socioeconomic class, pre-existent nutritional
75
deficiency might also contribute to the clinical scenario. Hence these
nutritional deficiencies, which are amenable for correction, if sought
earlier and corrected in the high risk group, might decrease the
incidence of this catastrophic disease.
Further large scale studies are needed to establish a clear
relationship between these factors in our population. Studies are also
needed in the context of treatment with folic acid, methyl cobalamine,
and pyridoxine in the acute setting of CVT. Further studies are also
needed in pregnant and the puerperal women who will also have
decreased folate levels due to increased demand. The appropriate dose
of folic acid needed to overcome these deficient states in various
population  subgroups needs to be quantified by further studies.
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Annexure I–Proforma
STUDY OF CEREBRAL VENOUS THROMBOSIS IN MALES
PROFOMA
Name :                                               Age :                      Sex :
Occupation :                                    Address : Ip No. :
Ward :
Neuro No.
Date of admission :                                    Date of  Discharge :
Socioeconomic status:
1. History of presenting neurological illness
A.H/o Headache, Seizures
B.Prior H/o Fever, Vomiting, Diarrhoea
C.Motor/sensory/cranial nerves/cerebellar/bladder symptoms.
D.Symptoms of  increased intracranial pressure
E. Symptoms of meningeal irritation
2. Past history
      Hypertension / diabetes mellitus / coronary heart disease /
dyslipidemia / Deep vein thrombosis / connective tissue disorders /
3. Personnel history
Smoking/Alcohol/Substance abuse (cocaine)
4. Family history
           Stroke / Diabetes / Hypertension
           Hypercoagulable state
5. Drug history
6. General examination
         Pulse rate:                 Blood pressure: lying : right       left
        Temperature:
        Respiratory rate:
        Pallor/polycythemia:
        Hydration:
7. Central nervous system examination:
      Consciousness / Glascow coma scale
       Pupil size, reaction to light.
     Cranial nerve examination including fundus.
  Examination of motor / sensory / cerebellar system to localize the
level of      lesion meningeal signs
8. Other systems:
          CVS :   first and second heart sounds / murmurs
          RS    :   breath sounds
          ENT           : Paranasal sinus / Mastoid tenderness
9. Investigations:
1. Haemoglobin, total count, differential counts
2. ESR
3. Coagulation profile
4. Blood sugar – random, if high - fasting and 2hour postprandial
5. Urea / creatinine
6. Electrolytes
7. Lipid profile
8. HIV – I & II
9. ANA(if positive ds DNA), APLA, ACLA, Sr.Homocysteine,
Sr.Fibrinogen,
10. Thyroid Function Test
11. X-Ray paranasal sinus/ ENT opinion
12. Electrocardiogram
13. Chest x ray
14. CT Brain with Contrast / MRI brain / MRV
Annexure II– Master Chart
Prog-
nosis
SSS TS SG,IJV HE DEEP CAV
MASTO-
IDITIS
Sinu-
sitis
Granu-
lomas
Carci-
noma
related
1 KUMERESAN 28 1924/11 N N Y Y N Y Y Y Y 13 N N N E N N N SSS N N A N N N N N N R
2 VINOTH 25 4536/11 Y Y Y Y N N N N N 15 N N N N N N N SSS N N A N N N N N N W
3 ANTONY RAJ 35 5554/11 Y Y Y N N Y N Y Y 15 N N N E N N N SSS N N A N N N N N N R
4 SURESH 24 5754/11 Y N Y Y N Y N N N 15 N N N E N N N SSS N N SAH N N N N N N R
5 SUBRAMANIUM 50 8871/11 Y N Y Y N N N N N 15 N N P N N N N SSS N N A N N N N N N W
6 PARTHIBAN 24 7680/11 Y Y Y Y N Y N N N 15 N N N E N N N SSS N N A N N N N N N R
7 AMALRAJ 25 8765/11 Y Y Y Y N Y N Y Y 15 N N N E N N N SSS N N A N N N N N N R
8 KRISHNAN 29 9452/11 Y Y Y N N N N N N 15 N N N N N N N SSS N N P N N N N N N W
9 MASTHAN 25 10561/11 Y Y Y N N Y N N N 15 N N N E N N N SSS N N A N N N N N N R
10 NAGAPPAN 45 672/12 Y Y Y Y N Y N Y N 15 N N N E N N N SSS TS N A N N N Y N N R
11 BALAKRISNAN 32 953/12 Y Y Y Y Y Y N Y Y 8 P N N E N N N SSS N N A P N N N N N D
12 MURUGAN 27 1127/12 Y Y Y N N N N N N 15 N N N N  N N N N TS SG A N N N Y N N R
13 KRISHNAMOORTHY 26 1092/12 Y Y Y Y Y Y N Y Y 3 N N N E N N N SSS N SG P P N N N N N D
14 SIRANJEEVI 34 1673/12 Y Y Y N Y Y N Y Y 10 P P P N N N N N TS SG P N N N Y N N W
15 NMANIKANDAN 35 2866/12 Y Y Y Y N Y Y Y Y 14 P N P E N N N N TS N A N N N Y N N W
16 RAGUPATHY 42 2943/12 Y Y Y Y N N N N N 15 N N N N N N N N TS N A N N N Y N N R
17 PANDIAN 47 1983/12 Y Y Y Y N Y Y Y Y 14 N N N E N N N SSS N N A P N N N N N W
18 DASS 43 3079/12 Y Y Y Y N Y N N Y 15 N N N E N N N SSS TS N P N N N N N N R
19 HUSSAIN 40 3274/12 Y Y Y Y N Y N Y N 14 N N N E N N N SSS TS N P N N N Y N N R
20 BALAIAH 63 3592/12 Y N Y N N N N N N 15 N N N N N N N N N SG,IJV A N N N N N Y R
21 PRAKASH 35 3853/12 Y Y Y Y N Y N N Y 15 N N N N N N N SSS TS N A P N N Y N N R
22 RAJENDRAN 40 4741/12 N N Y Y N Y N N N 15 N N N N N N N SSS TS N A N N N Y N N R
23 NAGAPPAN 45 4603/12 Y Y Y Y Y Y N N Y 14 N N N E N N N SSS N N A P, N N N N N R
24 SAKTHIVEL 35 5496/12 Y Y Y Y N Y N Y Y 14 N N N E N N N N TS SG P N N N Y N N W
25 DHOMADHARN 44 5597/12 Y N Y Y N N N N N 14 N N N N N N N SSS TS SG A N N N Y N N R
26 THIRUNAVUKARASU 46 5876/12 Y Y Y Y Y Y N N Y 15 P N N E N N N SSS N N A P N N Y N N R
27 SAHUL HAMEED 45 6234/12 Y Y Y Y N Y N N N 14 N N N E N N N N N SG A N N N Y N N R
28 MOORTHY 38 6573/12 Y N Y Y N Y N N N 15 N N N N N N N N N N A N N P Y N N R
29 SHANMUGAM 55 6732/12 Y Y Y Y N Y N N N 13 N N N N N N N N TS N A N N P Y N N R
30 VIKRAM 26 6582/12 N Y Y Y N Y N N N 15 N N N E N N N N TS SG A N N P Y N N R
31 MAHESH 36 6798/12 Y Y Y N N Y N N N 15 P N N E N N N SSS TS N A P N N Y N N R
32 SADHIQ 24 6990/12 Y Y Y Y N Y N N N 14 N N N E N N N SSS N N P P N N N N N R
33 TAMILSELVAN 50 5702/12 Y Y Y Y N Y N Y Y 15 N N N N N N N SSS TS SG A N N P Y N N R
34 OMAL 13 6519/12 N N Y Y Y Y N Y Y 13 N N N N N N N SSS TS N A N N N N N N R
35 KALAIVANNAN 27 8210/12 Y Y Y Y N N N N N 15 P N N N N N N N TS IJV A P N N N N Y R
36 SULTHAN 37 7945/12 Y Y Y N N Y N Y N 13 N N N E N N N SSS N N A N N N N N N R
Protein
S
Antith-
rombin
III
BP ANA LA
Anti
Cardio-
lipin
Ab
Homo-
cysteine
Protein
C
LOC Fits
Dys-
phasia
Hemi-
paresis
PAP GCS
MRI
S.
No
Name Age Sex
IP/OP
no
Smo-
king
Alco-
hol
Head
ache
Vomi-
ting
37 ELONGOVAN 25 7631/12 Y Y Y N N Y N Y N 14 P N N E N N N N TS SG A N N P Y N N R
38 VINOTH KUMAR 30 4762/12 N Y Y N N Y N Y N 15 N N N E N N N N TS IJV A N N N N N N R
39 ISMAIL 56 8612/12 Y Y Y Y N Y N Y S 15 N N N N N N N N TS SG A N N N Y N N R
40 VENKETESH 35 7496/12 N Y Y N N Y Y Y Y 13 N N N E N N N SSS N N P N N N N N N R
41 ABDUL KADHER 25 8672/12 N Y Y Y N Y N Y Y 11 N N N E N N N SSS N N P N N N N N N R
42 JOHN PETER 45 5249/12 N Y Y N N Y Y Y Y 12 N N N E N N N SSS N N P N N N N N N R
43 RAGHU 47 8945/12 N N Y Y N Y Y Y Y 13 P N N N N N N SSS N N P N N N N Y N W
44 SANDEEP 22 9123/12 Y Y Y Y N Y N Y N 15 N N N E N N N SSS N N P N N N N N N R
45 HARIDOSS 40 8764/12 y y Y Y N Y N Y N 15 N N N N N N N SSS N N A N N N N N N R
46 RAMANA 45 8826/12 Y N Y N N Y N Y Y 14 N N N N N N N N N N A N CAV N Y N N R
47 SANTHOSH 22 7927/12 Y Y Y N N Y Y Y N 14 N N N N N N N SSS N N P N N N N N N R
48 DAKSHANAMOORTHY34 6320/11 Y Y Y Y N Y N N Y 15 N N N N N N N SSS N SG A P N N N N N R
49 AYYAPPAN 34 3984/12 N Y Y N N Y N N N 15 N N N N N N N SSS TS IJV A N N N N N N R
50 BASU 35 0156/11 Y Y Y N N Y N N N 15 N N N E N N N SSS TS SG A N N N N N N R
51 GANESAN 50 6439/12 Y Y Y Y N Y N Y Y 15 N N N N N N N SSS TS SG A N N N N N N R
52 KARUNAI VEERAN 28 0371/13 Y Y Y Y N Y Y Y Y 13 P N N N N N N N TS SG P N N N N N N R
53 KAMALAKANNAN 23 109/13 N Y Y N N Y N N N 15 N N N N N N N SSS TS SG A N N Y N N N R
54 MAHENDRAN 33 783//13 Y Y Y N N Y N Y N 15 N N N N N N N SSS N N SAH N N N N N N RR
55 MARUDHAMUTHU 25 609/13 Y Y Y Y N Y N N N 15 N N N E N N N SSS N N A N N N N N N R
56 SOLAI 26 5794/10 Y Y Y Y N N N N N 15 N N N E N N E SSS N N A N N N N N N R
57 MAHESH 22 298/12 Y Y Y Y N N N N N 15 N N N N N N N SSS N N A N N N N N N W
58 DAMODHARAN 45 896/12 Y Y Y N N N N N N 15 N N N E N N N SSS N N A N N N N N N R
59 SATHISH KUMAR 28 1056/11 Y Y Y N N N N N N 15 P N N N N N N SSS N N A N N N N N N R
60 MOHAN 34 8243/12 Y N Y N N Y N N N 15 N N N E N N N N N N A N CAV N N N N R
Y = Present SG = Sigmoid  Sinus E = Elevated CAV = Cavernous Sinus
P = Positive IJV = Internal Jugular Vein SSS = Superior  Sagittal Sinus HE = Hemorrhage
N = Absent SAH = Subarachanoid  Hemorrhage TS = Transverse Sinus


